Cardiovascular diseases

Manual of Molecular and Clinical Laboratory Immunology: 7th edition

Volumn , Issue , 2022, Pages 1101-1109

  Sundstrom, J Bruce ^a   Burek, C Lynne ^b   Rose, Noel R ^b   Ansari, Aftab A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myocardial infarction (AMI); Cardiomyopathies; Cardiovascular diseases; Chronic myocardial injury (CMI); Diagnosis

Indexed keywords

EID: 85099425983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555815905.ch124     Document Type: Chapter

References (51)

1. Adams, J. E., III, D. R. Abendschein, and A. S. Jaffe. 1993. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 88:750-763.
2. Altieri, P., C. Brunelli, S. Garibaldi, A. Nicolino, S. Ubaldi, P. Spallarossa, L. Olivotti, P. Rossettin, A. Barsotti, and G. Ghigliotti. 2003. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur. J. Clin. Investig. 33:648-656.
3. Apple, F. S., H. E. Quist, P. J. Doyle, A. P. Otto, and M. M. Murakami. 2003. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin. Chem. 49:1331-1336.
4. Aretz, H. T. 1987. Myocarditis: the Dallas criteria. Hum. Pathol. 18:619-624.
5. Aretz, H. T., M. E. Billingham, W. D. Edwards, S. M. Factor, J. T. Fallon, J. J. Fenoglio, Jr., E. G. Olsen, and F. J. Schoen. 1987. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1:3-14.
6. Aukrust, P., T. Ueland, E. Lien, K. Bendtzen, F. Muller, A. K. Andreassen, I. Nordoy, H. Aass, T. Espevik, S. Simonsen, S. S. Froland, and L. Gullestad. 1999. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 83:376-382.
7. Eriksson, U., R. Ricci, L. Hunziker, M. O. Kurrer, G. Y. Oudit, T. H. Watts, I. Sonderegger, K. Bachmaier, M. Kopf, and J. M. Penninger. 2003. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med. 9:1484-1490.
8. Fairweather, D., Z. Kaya, G. R. Shellam, C. M. Lawson, and N. R. Rose. 2001. From infection to autoimmunity. J. Autoimmun. 16:175-186.
9. Feuerstein, G. Z., and D. Rozanski. 2000. G proteins and heart failure: is Gaq a novel target for heart failure? Circ. Res. 87:1085-1086.
10. Flesch, M., A. Hoper, L. Dell'Italia, K. Evans, R. Bond, R. Peshock, A. Diwan, T. A. Brinsa, C. C. Wei, N. Sivasubramanian, F. G. Spinale, and D. L. Mann. 2003. Activation and functional significance of the reninangiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 108:598-604.
11. Gotlieb, A. I., M. R. Freeman, T. A. Salerno, S. V. Lichtenstein, and P W. Armstrong. 1991. Ultrastructural studies of unstable angina in living man. Mod. Pathol. 4:75-80.
12. Guilherme, L., and J. Kalil. 2002. Rheumatic fever: the T cell response leading to autoimmune aggression in the heart. Autoimmun. Rev. 1:261-266.
13. Gullestad, L., P. Aukrust, T. Ueland, T. Espevik, G. Yee, R. Vagelos, S. S. Froland, and M. Fowler. 1999. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. 34:2061-2067.
14. Hill, S. L., and N. R. Rose. 2001. The transition from viral to autoimmune myocarditis. Autoimmunity 34:169-176.
15. Hillis, G. S., N. Zhao, P. Taggart, W. C. Dalsey, and A. Mangione. 1999. Utility of cardiac troponin I, creatine kinase-MB(mass), myosin light chain 1, and myoglobin in the early in-hospital triage of "high risk" patients with chest pain. Heart 82:614-620.
16. Inoue, T., T. Kato, K. Takayanagi, T. Uchida, I. Yaguchi, H. Kamishirado, S. Morooka, and N. Yoshimoto. 2003. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am. J. Cardiol. 92:1461-1464.
17. Kai, H., H. Ikeda, H. Yasukawa, M. Kai, Y. Seki, F. Kuwahara, T. Ueno, K. Sugi, and T. Imaizumi. 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32:368-372.
18. Kawai, C. 1999. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99:1091-1100.
19. Keffer, J. H. 1996. Myocardial markers of injury. Evolution and insights. Am. J. Clin. Pathol. 105:305-320.
20. Levin, E. R., D. G. Gardner, and W. K. Samson. 1998. Natriuretic peptides. N. Engl. J. Med. 339:321-328.
21. Li, Y. Y., C. F. McTiernan, and A. M. Feldman. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res. 46:214-224.
22. MacLellan, W. R., and A. J. Lusis. 2003. Dilated cardiomyopathy: learning to live with yourself. Nat. Med. 9:1455-1456.
23. Mair, J. 1997. Progress in myocardial damage detection: new biochemical markers for clinicians. Crit. Rev. Clin. Lab. Sci. 34:1-66.
24. Maisch, B., I. Portig, A. Ristic, G. Hufnagel, and S. Pankuweit. 2000. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz 25:200-209.
25. Mann, D. L. 2002. Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart. Cardiovasc. Drugs Ther. 16:7-9.
26. Mann, D. L. 2002. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91:988-998.
27. Mann, D. L. 2003. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu. Rev. Physiol. 65:81-101.
28. Marshall, T., J. Williams, and K. M. Williams. 1991. Electrophoresis of serum isoenzymes and proteins following acute myocardial infarction. J. Chromatogr. 569:323-345.
29. Mason, J. W. 1996. Immunopathogenesis and treatment of myocarditis: the United States Myocarditis Treatment Trial. J. Card. Fail. 2:S173-S177.
30. Mason, J. W. 2003. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc. Res. 60:5-10.
31. McCullough, P. A., R. M. Nowak, J. McCord, J. E. Hollander, H. C. Herrmann, P. G. Steg, P. Duc, A. Westheim, T. Omland, C. W. Knudsen, A. B. Storrow, W. T. Abraham, S. Lamba, A. H. Wu, A. Perez, P. Clopton, P. Krishnaswamy, R. Kazanegra, and A. S. Maisel. 2002. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106:416-422.
32. Noutsias, M., C. Hohmann, M. Pauschinger, P. L. Schwimmbeck, K. Ostermann, U. Rode, M. H. Yacoub, U. Kuhl, and H. P. Schultheiss. 2003. sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int. J. Cardiol. 91:153-161.
33. Panteghini, M., F. S. Apple, R. H. Christenson, F. Dati, J. Mair, and A. H. Wu. 1999. Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Scand. J. Clin. Lab. Investig. 230(Suppl.):103-112.
34. Pettersson, T., O. Ohlsson, and N. Tryding. 1992. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death. Eur. Heart J. 13:1387-1392.
35. Pope, J. H., T. P Aufderheide, R. Ruthazer, R. H. Woolard, J. A. Feldman, J. R. Beshansky, J. L. Griffith, and H. P. Selker. 2000. Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med. 342:1163-1170.
36. Prontera, C., M. Emdin, G. C. Zucchelli, A. Ripoli, C. Passino, and A. Clerico. 2003. Natriuretic peptides (NPs): automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin. Chem. 49:1552-1554.
37. Puleo, P. R., P A. Guadagno, R. Roberts, M. V. Scheel, A. J. Marian, D. Churchill, and M. B. Perryman. 1990. Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. Circulation 82:759-764.
38. Robers, M., F. F. Van der Hulst, M. A. Fischer, W. Roos, C. E. Salud, H. G. Eisenwiener, and J. F. Glatz. 1998. Development of a rapid microparticle-enhanced turbidimetric immunoassay for plasma fatty acid-binding protein, an early marker of acute myocardial infarction. Clin. Chem. 44:1564-1567.
39. Schwartzkopff, B., M. Fassbach, B. Pelzer, M. Brehm, and B. E. Strauer. 2002. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur. J. Heart Fail. 4:439-444.
40. Stewart, J. A., Jr., C. C. Wei, G. L. Brower, P. E. Rynders, G. H. Hankes, A. R. Dillon, P. A. Lucchesi, J. S. Janicki, and L. J. Dell'Italia. 2003. Cardiac mast cell- and chymase- mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J. Mol. Cell. Cardiol. 35:311-319.
41. Storrow, A. B., and W. B. Gibler. 2000. Chest pain centers: diagnosis of acute coronary syndromes. Ann. Emerg. Med. 35:449-461.
42. Suzuki, T., T. Yamazaki, and Y. Yazaki. 2001. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res. 51:489-494.
43. Tsutamoto, T., T. Hisanaga, A. Wada, K. Maeda, M. Ohnishi, D. Fukai, N. Mabuchi, M. Sawaki, and M. Kinoshita. 1998. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31:391-398.
44. Upadhya, B., J. L. Kontos, F. Ardeshirpour, J. Pye, W. S. Boucher, T. C. Theoharides, G. J. Dehmer, and E. N. Deliargyris. 2004. Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. J. Card. Fail. 10:31-35.
45. Wang, Y., M. Afanasyeva, S. L. Hill, and N. R. Rose. 1999. Characterization of murine autoimmune myocarditis induced by self and foreign cardiac myosin. Autoimmunity 31:151-162.
46. Wei, C. C., P. A. Lucchesi, J. Tallaj, W. E. Bradley, P. C. Powell, and L. J. Dell'Italia. 2003. Cardiac interstitial bradykinin and mast cells modulate pattern of LV remodeling in volume overload in rats. Am. J. Physiol. Heart. Circ. Physiol. 285:H784-H792.
47. Wettschureck, N., H. Rutten, A. Zywietz, D. Gehring, T. M. Wilkie, J. Chen, K. R. Chien, and S. Offermanns. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/ Galpha11 in cardiomyocytes. Nat. Med. 7:1236-1240.
48. Wollert, K. C., and H. Drexler. 2001. The role of interleukin-6 in the failing heart. Heart Fail. Rev. 6:95-103.
49. Wu, A. H., F. S. Apple, W. B. Gibler, R. L. Jesse, M. M. Warshaw, and R. Valdes, Jr. 1999. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 45:1104-1121.
50. Yamazaki, T., J. D. Lee, H. Shimizu, H. Uzui, and T. Ueda. 2004. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur. J. Heart Fail. 6:41-45.
51. Zolk, O., J. Quattek, U. Seeland, A. El-Armouche, T. Eschenhagen, and M. Bohm. 2002. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc. Res. 53:363-371.